The global nanotechnology drug delivery market size is accounted at USD 105.95 billion in 2025 and is forecasted to hit around USD 209.73 billion by 2034, representing a CAGR of 7.91% from 2025 to 2034. The North America market size was estimated at USD 39.19 billion in 2024 and is expanding at a CAGR of 7.94% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Nanotechnology Drug Delivery Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Nanotechnology Drug Delivery Market, by Technology
8.1.1. Nanocrystals
8.1.1.1. Market Revenue and Forecast
8.1.2. Nanoparticles
8.1.2.1. Market Revenue and Forecast
8.1.3. Liposomes
8.1.3.1. Market Revenue and Forecast
8.1.4. Micelles
8.1.4.1. Market Revenue and Forecast
8.1.5. Nanotubes
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast
9.1. Nanotechnology Drug Delivery Market, by Application
9.1.1. Neurology
9.1.1.1. Market Revenue and Forecast
9.1.2. Oncology
9.1.2.1. Market Revenue and Forecast
9.1.3. Cardiovascular/Physiology
9.1.3.1. Market Revenue and Forecast
9.1.4. Anti-Inflammatory / Immunology
9.1.4.1. Market Revenue and Forecast
9.1.5. Anti-infective
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Technology
10.1.2. Market Revenue and Forecast, by Application
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Technology
10.1.3.2. Market Revenue and Forecast, by Application
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Technology
10.1.4.2. Market Revenue and Forecast, by Application
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology
10.2.2. Market Revenue and Forecast, by Application
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Technology
10.2.3.2. Market Revenue and Forecast, by Application
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Technology
10.2.4.2. Market Revenue and Forecast, by Application
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Technology
10.2.5.2. Market Revenue and Forecast, by Application
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Technology
10.2.6.2. Market Revenue and Forecast, by Application
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology
10.3.2. Market Revenue and Forecast, by Application
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Technology
10.3.3.2. Market Revenue and Forecast, by Application
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Technology
10.3.4.2. Market Revenue and Forecast, by Application
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Technology
10.3.5.2. Market Revenue and Forecast, by Application
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Technology
10.3.6.2. Market Revenue and Forecast, by Application
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology
10.4.2. Market Revenue and Forecast, by Application
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Technology
10.4.3.2. Market Revenue and Forecast, by Application
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Technology
10.4.4.2. Market Revenue and Forecast, by Application
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Technology
10.4.5.2. Market Revenue and Forecast, by Application
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Technology
10.4.6.2. Market Revenue and Forecast, by Application
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology
10.5.2. Market Revenue and Forecast, by Application
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Technology
10.5.3.2. Market Revenue and Forecast, by Application
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Technology
10.5.4.2. Market Revenue and Forecast, by Application
11.1. Novartis International AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Taiwan Liposome Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Johnson and Johnson
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Merck and Co., Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Tarveda Therapeutics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Celgene Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. AbbVie, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Amgen, Inc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Nanobiotix
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. NanoCarrier Corporation
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client